Drug Patents owned by Axsome Malta
1. List of Sunosi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11439597 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(14 years from now) | |
| US11560354 | AXSOME MALTA | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof |
Mar, 2039
(15 years from now) | |
| US11160779 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(16 years from now) | |
Do you want to check out SUNOSI patents from before 2022?
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity (ODE) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 2023-06-18
Market Authorisation Date: 17 June, 2019
Treatment: Treatment of excessive daytime sleepiness by adminstering a composition comprising solriamfetol hydrochloride and 2-chloropropane, wherein the composition comprises less than about 5 ppm 2-chloropropa...
Dosage: TABLET;ORAL
More Information on Dosage
SUNOSI family patents
6
United States
1
Korea, Republic of
1
China
1
Russia
1
Philippines
1
Chile
1
Israel
1
Canada
1
Singapore
1
Mexico
1
Japan
1
Australia
1
Denmark
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic